IL160271A0 - Pharmaceutical compositions containing pde4-inhibitors and nsaid - Google Patents

Pharmaceutical compositions containing pde4-inhibitors and nsaid

Info

Publication number
IL160271A0
IL160271A0 IL16027102A IL16027102A IL160271A0 IL 160271 A0 IL160271 A0 IL 160271A0 IL 16027102 A IL16027102 A IL 16027102A IL 16027102 A IL16027102 A IL 16027102A IL 160271 A0 IL160271 A0 IL 160271A0
Authority
IL
Israel
Prior art keywords
nsaid
inhibitors
pharmaceutical compositions
compositions containing
derivative
Prior art date
Application number
IL16027102A
Other languages
English (en)
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of IL160271A0 publication Critical patent/IL160271A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL16027102A 2001-09-19 2002-09-17 Pharmaceutical compositions containing pde4-inhibitors and nsaid IL160271A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01000473 2001-09-19
PCT/EP2002/010424 WO2003024489A2 (en) 2001-09-19 2002-09-17 Combination of a nsaid and a pde-4 inhibitor

Publications (1)

Publication Number Publication Date
IL160271A0 true IL160271A0 (en) 2004-07-25

Family

ID=8176065

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16027102A IL160271A0 (en) 2001-09-19 2002-09-17 Pharmaceutical compositions containing pde4-inhibitors and nsaid
IL160271A IL160271A (en) 2001-09-19 2004-02-08 Pharmaceutical compositions containing pde4-inhibitors and

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL160271A IL160271A (en) 2001-09-19 2004-02-08 Pharmaceutical compositions containing pde4-inhibitors and

Country Status (25)

Country Link
US (2) US20040242597A1 (es)
EP (1) EP1429807B1 (es)
JP (1) JP4588998B2 (es)
KR (1) KR100949528B1 (es)
CN (1) CN100496607C (es)
AT (1) ATE355080T1 (es)
AU (1) AU2002337105B2 (es)
BR (1) BR0212606A (es)
CA (1) CA2459757C (es)
CY (1) CY1108011T1 (es)
DE (1) DE60218497T2 (es)
DK (1) DK1429807T3 (es)
EA (1) EA008108B1 (es)
ES (1) ES2282469T3 (es)
HK (1) HK1066730A1 (es)
HU (1) HU229442B1 (es)
IL (2) IL160271A0 (es)
MX (1) MXPA04002562A (es)
NO (1) NO331756B1 (es)
NZ (1) NZ532278A (es)
PL (1) PL210463B1 (es)
PT (1) PT1429807E (es)
SI (1) SI1429807T1 (es)
WO (1) WO2003024489A2 (es)
ZA (1) ZA200402654B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004110424A1 (en) * 2003-05-28 2004-12-23 Glaxo Group Limited Method and pharmaceutical formulation for reducing stress-induced accelerated colonic transit in a mammal
WO2005016334A1 (en) * 2003-08-07 2005-02-24 B.M.R.A. Corporation B.V. Compositions and methods involving the combination of a thromboxane a2 receptor antagonist and an inhibitor of cyclooxigenase-1
BRPI0415753A (pt) * 2003-10-21 2006-12-19 Pharmacia Corp método para tratamento e prevenção da inflamação respiratória com um inibidor de ciclooxigenase-2 em associação com um inibidor de fosfodiesterase 4 e composições que os contêm
EP1683521A1 (en) * 2005-01-21 2006-07-26 Centre National De La Recherche Scientifique (Cnrs) Peptide deformylase inhibitors, their use, and pharmaceutical compositions containing the same
EP1688413A1 (en) * 2005-02-03 2006-08-09 Hikma Pharmaceuticals Co. Ltd. Benzoxazole derivatives for the prophylaxis and treatment of inflammatory bowel diseases
AU2006224623A1 (en) * 2005-03-14 2006-09-21 Nycomed Gmbh Method for preventing cardiovascular diseases
EP1898894A1 (en) * 2005-06-17 2008-03-19 Boehringer Ingelheim International GmbH Mrp iv inhibitors for the treatment of respiratory diseases
KR101517064B1 (ko) * 2006-04-28 2015-04-30 그뤼넨탈 게엠베하 3-(3-디메틸아미노-1-에틸-2-메틸-프로필)-페놀 및 nsaid를 포함하는 약제학적 병용제
FR2909876A1 (fr) * 2006-12-19 2008-06-20 Galderma Res & Dev S N C Snc Utilisation du nepafenac ou ses derives pour le traitement de desordres dermatologiques
EP2244574B1 (en) 2008-01-25 2014-10-01 High Point Pharmaceuticals, LLC Tricyclic compounds as modulators of tnf- synthesis and as pde4 inhibitors
BRPI0908276B8 (pt) * 2008-03-04 2021-05-25 Labrys Biologics Inc uso de um anticorpo antagonista anti-cgrp para a fabricação de um medicamento para a prevenção e/ou tratamento de dor de osteoartrite
EP2400961B1 (de) * 2009-02-27 2017-11-22 Boehringer Ingelheim International GmbH Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids
WO2010097334A1 (de) * 2009-02-27 2010-09-02 Boehringer Ingelheim International Gmbh Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids
KR20150119370A (ko) 2013-02-19 2015-10-23 화이자 인코포레이티드 Cns 장애 및 다른 장애의 치료를 위한 pde4 동종효소의 억제제로서의 아자벤즈이미다졸 화합물
WO2016012896A1 (en) 2014-07-24 2016-01-28 Pfizer Inc. Pyrazolopyrimidine compounds
HUE044040T2 (hu) 2014-08-06 2019-09-30 Pfizer Imidazopiridazin vegyületek
WO2019147824A1 (en) 2018-01-26 2019-08-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
WO2021113498A1 (en) * 2019-12-03 2021-06-10 The Usa, As Represented By The Secretary, Department Of Health And Human Services Cyclooxygenase-2 inhibition for the treatment of saa-high asthma
US11707610B2 (en) 2019-12-13 2023-07-25 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US20230090417A1 (en) * 2021-09-22 2023-03-23 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1229075B (it) 1985-04-05 1991-07-17 Fidia Farmaceutici Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico
GB2228736A (en) 1989-02-10 1990-09-05 Sterivet Lab Ltd Cosmetic formulation
ES2137113B1 (es) * 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.
SK6252000A3 (en) 1997-11-04 2001-11-06 Pfizer Prod Inc Indazole bioisostere replacement of catechol in therapeutically active compounds
WO2001000229A1 (en) 1999-06-24 2001-01-04 Pharmacia Corporation Combination of tumors necrocis factor (tnf) antagonists and cox-2 inhibitors for the treatment of inflammation
IL147688A0 (en) * 1999-08-21 2002-08-14 Byk Gulden Lomberg Chem Fab Synergistic combination
US6174878B1 (en) * 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
ECSP003747A (es) * 1999-11-02 2002-05-23 Smithkline Beecham Corp Metodo y composiciones para el tratamiento de las enfermedades pulmonares
US6410563B1 (en) * 1999-12-22 2002-06-25 Merck Frosst Canada & Co. Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
US6372777B1 (en) * 1999-12-23 2002-04-16 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
EE200200425A (et) * 2000-01-31 2003-10-15 Pfizer Products Inc. Selektiivsete PDE4 isosüümide inhibiitoritena kasulikud nikotiinamiidi bensokondenseerunud heterotsüklüülderivaadid
CA2398184A1 (en) * 2000-02-08 2001-08-16 Smithkline Beecham Corporation Method and compositions for treating an inflammatory disease
IL156460A0 (en) * 2001-01-31 2004-01-04 Pfizer Prod Inc Ether derivatives useful as inhibitors of pde4 isozymes
EA200300836A1 (ru) * 2001-02-15 2004-02-26 Алтана Фарма Аг Производные фталазинон-пиперидина в качестве ингибиторов pde4

Also Published As

Publication number Publication date
EA008108B1 (ru) 2007-04-27
EP1429807A2 (en) 2004-06-23
US20080255209A1 (en) 2008-10-16
CY1108011T1 (el) 2013-09-04
US20040242597A1 (en) 2004-12-02
CA2459757A1 (en) 2003-03-27
DK1429807T3 (da) 2007-06-18
US8242146B2 (en) 2012-08-14
NZ532278A (en) 2006-02-24
KR20040053129A (ko) 2004-06-23
EA200400410A1 (ru) 2004-12-30
KR100949528B1 (ko) 2010-03-25
HK1066730A1 (en) 2005-04-01
DE60218497D1 (de) 2007-04-12
SI1429807T1 (sl) 2007-08-31
JP2005504077A (ja) 2005-02-10
HU229442B1 (hu) 2013-12-30
CN1625411A (zh) 2005-06-08
JP4588998B2 (ja) 2010-12-01
AU2002337105B2 (en) 2008-03-20
WO2003024489A3 (en) 2003-09-18
NO331756B1 (no) 2012-03-19
PL369472A1 (en) 2005-04-18
WO2003024489A2 (en) 2003-03-27
ZA200402654B (en) 2005-04-26
NO20041596L (no) 2004-06-18
CN100496607C (zh) 2009-06-10
IL160271A (en) 2008-03-20
DE60218497T2 (de) 2007-11-08
HUP0401582A3 (en) 2008-04-28
PL210463B1 (pl) 2012-01-31
EP1429807B1 (en) 2007-02-28
CA2459757C (en) 2011-08-30
MXPA04002562A (es) 2004-05-31
BR0212606A (pt) 2004-08-17
PT1429807E (pt) 2007-05-31
ES2282469T3 (es) 2007-10-16
ATE355080T1 (de) 2006-03-15
HUP0401582A2 (hu) 2004-11-29

Similar Documents

Publication Publication Date Title
IL160271A0 (en) Pharmaceutical compositions containing pde4-inhibitors and nsaid
BRPI0411825A (pt) inibidores de p38 quinase a base de heterociclo de 5 elementos
CY1108274T1 (el) Μακροβιο ομοιαζον με γλυκογονο πεπτιδιο 2 (glp-2) για την θεραπεια γαστρεντερικων ασθενειων και διαταραχων
TW200511992A (en) Sulfonamide substituted imidazoquinolines
BR9914718A (pt) Formulações farmacêuticas de libertação controlada compreendendo um inibidor cgmp pde-5
EP1900362A3 (en) Alfa-aminoamide derivatives useful in the treatment of addictive disorders
DK1198233T3 (da) Sulfonamid- og sulfamidsubstituerede imidazoquinoliner
MXPA04001088A (es) Derivados de pirazol como inhibidores de cinasa y uso de los mismos.
IS7202A (is) Samsetningar til meðhöndlunar á ónæmisbólgusjúkdómum
MXPA02009551A (es) Profarmacos de derivados de imidazopiridina.
SE0102808D0 (sv) New compounds
HUP0401633A2 (hu) Irbesartan alkalmazása pulmonális magas vérnyomás megelőzésére vagy kezelésére alkalmas gyógyszerkészítmény előállítására
AR045724A1 (es) Composicion farmaceutica orodispersable de un compuesto antitrombotico
YU83903A (sh) Farmaceutske kombinacije zasnovane na derivatima piridoindolona
EA200100876A2 (ru) Фармацевтическая композиция для предупреждения или лечения заболевания, связанного с избыточным продуцированием il-12

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed